hydroxyproline and Cirrhosis, Liver studies

Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.

Research Excerpts

Excerpt	Relevance	Reference
"To study the effect of total flavonoids of Astmgali Radix (TFA) on liver cirrhosis induced with dimethylnitrosamine (DMN) in rats, and the effect on peroxisome proliferator-activated receptor γ (PPARγ), uncoupling protein 2 (UCP2) and farnesoid X receptor (FXR)."	7.85	Antifibrotic effect of total flavonoids of Astmgali Radix on dimethylnitrosamine-induced liver cirrhosis in rats. ( Chen, GF; Cheng, Y; Mai, JY; Ping, J; Wang, MF, 2017)
" NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and soluble intercellular adhesion molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and α-smooth muscle actin (SMA) expression."	7.77	Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. ( Dong, X; Jiang, H; Jiang, X; Kang, K; Kanwar, JR; Li, J; Pan, S; Qiao, H; Sun, X; Tan, G; Zhao, M, 2011)
"In 50 patients with a laparoscopically ascertained liver cirrhosis the hydroxyproline excretion was estimated in the 24-hour-urine."	7.66	[Urinary hydroxyproline excretion in liver cirrhosis]. ( Bretzke, G; List, A; Stahl, E, 1978)
"Cholestasis is a disorder characterized by impaired bile flow and accumulation of cytotoxic bile acids in the liver."	5.48	Dithiothreitol supplementation mitigates hepatic and renal injury in bile duct ligated mice: Potential application in the treatment of cholestasis-associated complications. ( Ahmadi, A; Azarpira, N; Esfandiari, A; Ghanbarinejad, V; Heidari, R; Mohammadi, H; Niknahad, H, 2018)
" Inflammation and fibrosis were evaluated by transaminases, myeloperoxidase activity, hydroxyproline, and histological evaluation."	4.12	Chronic intermittent hypoxia promotes early intrahepatic endothelial impairment in rats with nonalcoholic fatty liver disease. ( Abrante, B; Abreu-González, P; de la Barreda, R; Díaz-Flores, F; González-Paredes, FJ; Hernández-Bustabad, A; Hernández-Guerra, M; Morales-Arraez, D; Quintero, E, 2022)
"To study the effect of total flavonoids of Astmgali Radix (TFA) on liver cirrhosis induced with dimethylnitrosamine (DMN) in rats, and the effect on peroxisome proliferator-activated receptor γ (PPARγ), uncoupling protein 2 (UCP2) and farnesoid X receptor (FXR)."	3.85	Antifibrotic effect of total flavonoids of Astmgali Radix on dimethylnitrosamine-induced liver cirrhosis in rats. ( Chen, GF; Cheng, Y; Mai, JY; Ping, J; Wang, MF, 2017)
" Starting from the third week, rats were exposed to 40 % carbon tetrachloride (CCl4; 150 μl/100 g body weight twice weekly, initially 200 μl/100 g) treatment for a duration of 8 weeks."	3.81	A Targeted Multiple Antigenic Peptide Vaccine Augments the Immune Response to Self TGF-β1 and Suppresses Ongoing Hepatic Fibrosis. ( Dang, S; Jia, X; Li, Y; Wang, W; Wang, X; Wang, Y; Zhai, S, 2015)
" Our results showed that DMN-induced hepatic pathological damage significantly decreased the body weight and liver index, increased the mRNA and protein levels of collagen α-1(I) (ColIα-1) and α-smooth muscle actin, and increased the hydroxyproline content."	3.80	Lactoferrin protects against chemical-induced rat liver fibrosis by inhibiting stellate cell activation. ( Chen, CM; Chen, HL; Cheng, WT; Chong, KY; Tang, TY; Tung, YT; Yang, SH, 2014)
" The granuloma area, hepatic hydroxyproline (HYP) level and hepatic fibrosis of the protein therapeutic groups were significantly smaller than those of the positive control group (P<0."	3.80	The effect of recombinant sTGFβ1RII and sIL13Rα2 receptor proteins on schistosomiasis japonica, hepatic fibrosis and signal transduction in a mouse model of schistosome disease. ( Chu, D; Yao, Y; Zhou, C, 2014)
" After a 2-week treatment, following parameters were observed: (1) last body weight, weight ratio between liver and spleen; (2) content of liver hydroxyproline (Hyp); (3) activity of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (gamma-GT), content of albumin (Alb) and total bilirubin( TBiL) in serum; (4) liver pathology (Sirius red staining and HE staining); (5) activity of liver superoxide dismutase (SOD), glutathione reduced (GSH), glutathione peroxidase (GSH-Px) and content of liver maleic dialdehyde (MDA)."	3.78	[Effect of gypenosides on DMN-induced liver fibrosis in rats]. ( Duan, X; Feng, Q; Fu, Q; Hu, Y; Li, X; Peng, J, 2012)
"Characteristics of thioacetamide (TAA)-induced liver cirrhosis in rat was observed for 120 days after TAA withdrawal as part of the radiobiological study of partial liver irradiation on TAA-induced cirrhotic rats."	3.77	A natural process of cirrhosis resolution and deceleration of liver regeneration after thioacetamide withdrawal in a rat model. ( Gu, K; Jiang, GL; Lai, ST; Liu, J; Ma, NY; Ren, ZG; Wang, J; Zhao, JD, 2011)
" NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and soluble intercellular adhesion molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and α-smooth muscle actin (SMA) expression."	3.77	Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. ( Dong, X; Jiang, H; Jiang, X; Kang, K; Kanwar, JR; Li, J; Pan, S; Qiao, H; Sun, X; Tan, G; Zhao, M, 2011)
"6 g/kg bw) significantly reduced the serum levels of alanine aminotransferase and aspartate aminotransferase in rats treated with CCl4, and also decreased the thiobarbituric acid reactive substances, hydroxyproline and excessive inflammation in the livers of CCl4-treated rats."	3.76	Hepatoprotection by freshwater clam extract against CCl4-induced hepatic damage in rats. ( Hsu, CC; Hsu, CL; Yen, GC, 2010)
"MR elastography of the liver was performed in 10 rats with hepatic fibrosis induced by intraperitoneal carbon tetrachloride (CCl(4)) injections and five normal rats."	3.74	Hepatic viscoelastic parameters measured with MR elastography: correlations with quantitative analysis of liver fibrosis in the rat. ( Abarca-Quinones, J; Annet, L; Leclercq, I; Peeters, F; Salameh, N; Sinkus, R; Ter Beek, LC; Van Beers, BE, 2007)
"In 50 patients with a laparoscopically ascertained liver cirrhosis the hydroxyproline excretion was estimated in the 24-hour-urine."	3.66	[Urinary hydroxyproline excretion in liver cirrhosis]. ( Bretzke, G; List, A; Stahl, E, 1978)
"Elastin fibers formation was previously found to be an important feature of advanced human liver cirrhosis."	3.66	Elastin fibers formation in the liver of carbon tetrachloride-treated rats. ( Bartos, F; Kanta, J, 1978)
"Ninety-eight patients with liver cirrhosis were divided into 2 groups randomly."	2.70	[Clinical and experimental study on anti-liver fibrosis effect of xuelong granule]. ( Li, ZZ; Sui, ZY; Wang, X, 2001)
"And 47 medium chronic hepatitis B viral fibrosis patients were studied."	2.70	Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis. ( Cai, WM; Liu, RH; Weng, HL, 2001)
"Confirm the anti-liver fibrosis effect of QWTX and reveal its mechanism from the perspective of NOD-like receptor protein 3 (NLRP3) inflammasome activation."	2.44	The anti-liver fibrosis effect of Tibetan medicine (Qiwei Tiexie capsule) is related to the inhibition of NLRP3 inflammasome activation in vivo and in vitro. ( Chen, M; Du, Q; Guo, H; Li, H; Lowe, S; Ren, Q; Sun, S; Wang, S; Wang, Z; Xia, W; Ye, F; Zhang, S, 2024)
"Despite the fact that liver fibrosis is an intractable disease with a poor prognosis, effective therapeutic agents are not available."	1.91	Therapeutic Effects of Albumin-Fused BMP7 on 2 Experimental Models of Liver Fibrosis. ( Imafuku, T; Maeda, H; Maruyama, T; Minayoshi, Y; Nakano, T; Nishida, K; Takano, M; Toda, S; Watanabe, H, 2023)
" The greater dosage of 0."	1.62	The involvement of TGF-β1 /FAK/α-SMA pathway in the antifibrotic impact of rice bran oil on thioacetamide-induced liver fibrosis in rats. ( Abd El-Rahman, SS; Abdel-Rahman, RF; Arbid, MS; Asaad, GF; Fayed, HM; Hessin, AF; Mohamed, MAE; Ogaly, HA; Salama, AAA, 2021)
"Calcitriol treatment attenuates intestinal permeability, reduces bacterial translocation, and enriches potentially beneficial gut microbiota in cirrhotic rats that may enable it as a potential therapeutic agent to prevent cirrhotic complications."	1.62	Active Vitamin D ( Hou, MC; Hsieh, YC; Huang, YH; Huo, TI; Lee, KC; Lee, PC; Li, CP; Lin, CH; Lin, HC; Yang, UC, 2021)
"Previously, LQ was found to inhibit liver fibrosis progression."	1.56	Liquiritigenin suppresses the activation of hepatic stellate cells via targeting miR-181b/PTEN axis. ( Dong, P; Fan, S; Geng, W; Li, C; Xiao, Q; Zhao, B; Zheng, J; Zhou, G, 2020)
"Ursodeoxycholic acid (UDCA) has been widely used in the treatment of primary biliary cholangitis (PBC) with chronic liver fibrosis, but its detailed mechanism remains unclear."	1.56	Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. ( Chen, L; Chen, XZ; Wu, PB; Ye, HL; Zhang, G; Zhang, JW, 2020)
"Build-up of extracellular matrix in liver fibrosis results in changes on endogenous molecules expression that may be studied through the fluorescence characterization of ex vivo liver samples."	1.56	Endogenous Fluorescence Dissimilarity Assessment of Four Potential Biomarkers of Early Liver Fibrosis by Preservation Media Effect. ( Franco, W; Gutierrez-Herrera, E; Hernández-Ruiz, J; Padilla-Castaneda, MA; Perez-Garcia, A; Sánchez-Pérez, C, 2020)
"Characteristics of nonalcoholic steatohepatitis-related liver fibrosis in KO-MCD/HF group were verified by hepatic histological analyses."	1.56	CREBH knockout accelerates hepatic fibrosis in mouse models of diet-induced nonalcoholic fatty liver disease. ( Jiang, Q; Li, G; Liu, B; Xu, K; Zhang, J, 2020)
"Early detection and accurate staging of liver fibrosis is critically important for patient management."	1.51	Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH). ( Boominathan, R; Cheng, P; Chong, YC; Deng, X; Goggi, JL; Han, W; Hartimath, SV; Robins, EG; Soh, V; Tan, PW; Yong, FF, 2019)
" However, whether long-term administration of DB will cause liver fibrosis in mice is unknown."	1.51	Long-term diosbulbin B treatment induced liver fibrosis in mice. ( Guan, H; Ji, L; Miao, H; Wang, C; Wang, Z; Zhang, Y, 2019)
"Carbon tetrachloride (CCl4) was used to induce liver fibrosis in mice, and locostatin was injected intraperitoneally."	1.51	Locostatin Alleviates Liver Fibrosis Induced by Carbon Tetrachloride in Mice. ( Jiang, H; Ma, J; Qiu, Y; Wang, M; Zhang, M; Zhao, X, 2019)
"Cholestasis is a disorder characterized by impaired bile flow and accumulation of cytotoxic bile acids in the liver."	1.48	Dithiothreitol supplementation mitigates hepatic and renal injury in bile duct ligated mice: Potential application in the treatment of cholestasis-associated complications. ( Ahmadi, A; Azarpira, N; Esfandiari, A; Ghanbarinejad, V; Heidari, R; Mohammadi, H; Niknahad, H, 2018)
" In summary, Nrf2 is critically involved in preventing liver fibrosis induced by long-term administration of APAP in mice, and Andro alleviates APAP-induced liver fibrosis by attenuating liver oxidative stress injury via inducing Nrf2 activation."	1.48	Natural product andrographolide alleviated APAP-induced liver fibrosis by activating Nrf2 antioxidant pathway. ( Bai, Q; Hao, Z; Huang, Z; Ji, L; Sheng, Y; Wang, Z; Yan, H, 2018)
"Therapeutic interventions for liver fibrosis are still limited due to the complicated molecular pathogenesis."	1.48	Renin-angiotensin system inhibition ameliorates CCl ( Abdelghany, RH; El-Ahwany, E; Helal, NS; Mahmoud, AAA; Saber, S, 2018)
"Liver fibrosis is excessive accumulation of extracellular matrix proteins that results from various chronic liver diseases."	1.48	A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo. ( Guo, T; Liu, CH; Liu, ZL; Zhao, Q; Zhao, ZM, 2018)
"Pretreatment with tadalafil protected against TAA-induced liver fibrosis, in a dose-dependent manner, as proved by the alleviation of inflammatory and fibrotic biomarkers."	1.48	The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats. ( Abdel-Salam, RM; Ahmed, NA; Mansour, HM; Salama, AAA; Yassen, NN; Zaki, HF, 2018)
" The present study was designed to investigate the possible protective effects of diethylcarbamazine (DEC) (50mg/kg, acting as an anti-inflammatory drug, interferes with the arachidonic acid metabolism) when administrated in combination with hesperidin (HDN) (200mg/kg, a flavanone glycoside with potent antioxidant and anti-inflammatory activities) against alcoholic liver fibrosis in wistar rats compared to silymarin (Sil) (100mg/kg)."	1.46	Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. ( El-Sisi, AEE; Mohamed, DZ; Shebl, AM; Sokar, SS, 2017)
"Liver fibrosis is a pathological process complicating schistosomiasis."	1.46	Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis. ( Ashour, RH; Elhenawy, AA; Megahed, N; Nabih, N; Shalaby, NM, 2017)
"Here, we use this strategy in the liver fibrosis induced by CCl4."	1.46	Preconditioning with melatonin improves therapeutic outcomes of bone marrow-derived mesenchymal stem cells in targeting liver fibrosis induced by CCl4. ( Hosseini, A; Kashani, IR; Khanlarkhani, N; Majidpoor, J; Mortezaee, K; Nekoonam, S; Pasbakhsh, P; Sabbaghziarani, F; Zendedel, A, 2017)
"BDL animal model of liver fibrosis was used in the study."	1.46	HIF-1 α as a Key Factor in Bile Duct Ligation-Induced Liver Fibrosis in Rats. ( Debek, W; Hermanowicz, A; Lebensztejn, DM; Miltyk, W; Moczydlowska, J; Palka, JA, 2017)
"Carvedilol co-treatment in CCl4-intoxicated rats for 6 weeks significantly counteracted the changes in hepatotoxicity markers and histopathological lesions induced by CCl4."	1.46	Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. ( Abdel-Sattar, SA; El-Bakly, WM; El-Demerdash, E; Mohamed, EA, 2017)
"Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect."	1.42	Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. ( Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S, 2015)
"Liver fibrosis is a pathological condition in which chronic inflammation and changes to the extracellular matrix lead to alterations in hepatic tissue architecture and functional degradation of the liver."	1.42	Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. ( Bettaieb, A; Chiamvimonvat, N; Dong, H; Haj, FG; Hammock, BD; Harris, TR; Kodani, S; Myers, R, 2015)
"We studied the development of liver fibrosis induced by thioacetamide (TAA) in knockout (PTTG-/-) and wildtype (PTTG+/+) mice."	1.42	Pituitary tumor transforming gene as a novel regulatory factor of liver fibrosis. ( Belonovskaya, E; Buko, V; Kanyuka, O; Kranc, R; Lukivskaya, O; Naruta, E; Stoika, R; Sybirna, N; Zhuk, O, 2015)
"Theophylline treated rats exhibited a significant decrease in hepatic vacuolation, apoptosis, leucocyte infiltration, and accumulation of collagen fibers in comparison to the Con A group."	1.42	Theophylline, an old drug with multi-faceted effects: Its potential benefits in immunological liver injury in rats. ( Elsirafy, OM; Hamam, GG; Hasanin, AH; Hussein, RM; Kawy, HS; Wahba, YS, 2015)
"The CCl4‑induced rats exhibited liver fibrosis, increased hydroxyproline content, impaired liver function, upregulated expression levels of the α‑SMA and TGF‑β1 pro‑fibrogenic proteins, and increased expression of HSP70, compared with the control group."	1.42	Geranylgeranylacetone attenuates hepatic fibrosis by increasing the expression of heat shock protein 70. ( Chen, B; Chen, J; He, W; Qi, L; Shao, D; Wang, L; Wang, M; Zhuang, Y, 2015)
"The therapeutic effects on liver fibrosis of sorafenib, a multiple tyrosine kinase inhibitor, and gadolinium chloride (GdCl3), which depletes KCs, were evaluated in rats."	1.42	Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats. ( Chen, X; Liu, C; Lu, Y; Miao, H; Tang, B; Wang, L; Xu, Q; Yang, Z, 2015)
"1."	1.40	Probucol attenuates ethanol-induced liver fibrosis in rats by inhibiting oxidative stress, extracellular matrix protein accumulation and cytokine production. ( Lin, Y; Su, X; Wang, Y; Yang, X; Yu, R; Zheng, C; Zhou, G, 2014)
"Sophocarpine was injected intraperitoneally in two distinct rat hepatic fibrosis models induced either by dimethylnitrosamine or bile duct ligation."	1.40	Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats. ( Chen, SW; Chen, YX; Fan, TT; Lv, J; Qian, H; Shi, J; Song, CY; Xie, WF; Zheng, ZW, 2014)
"However, the effects of WHP on liver fibrosis remain unknown."	1.40	Whey-hydrolyzed peptide-enriched immunomodulating diet prevents progression of liver cirrhosis in rats. ( Endo, K; Hori, T; Iwaisako, K; Jobara, K; Kaido, T; Uchida, Y; Uemoto, S, 2014)
"Advanced liver fibrosis results in cirrhosis and liver failure, and liver transplantation is often the only option for effective therapy; however, the shortage of available donor livers limits this treatment."	1.40	Therapeutic potential of amniotic-fluid-derived stem cells on liver fibrosis model in mice. ( Chen, YH; Cheng, PJ; Cheng, WT; Chou, CJ; Kao, YJ; Ko, IC; Peng, SY; Shaw, SW; Wu, SC, 2014)
"Acute hepatic injury and liver fibrosis in mice were induced by CCl4."	1.40	Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis. ( Liu, CH; Liu, ZL; Shen, L; Tao, YY; Yan, XC; Zhou, T, 2014)
"However, the role of IL-17 in liver fibrosis has not yet been elucidated."	1.39	Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. ( Fujii, H; Furuya, S; Hara, M; Hirayama, K; Kono, H; Tsuchiya, M, 2013)
"Liver fibrosis was induced by intraperitoneal injection of carbon tetrachloride (CCl₄) with or without curcumin for 6 weeks."	1.39	Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. ( Li, X; Lin, Y; Shen, X; Tu, C; Wang, J; Yao, Q, 2013)
"Liver fibrosis was induced in male Sprague-Dawley (SD) rats by the subcutaneous injection of CCl4."	1.39	Recombinant human histidine triad nucleotide-binding protein 1 attenuates liver fibrosis induced by carbon tetrachloride in rats. ( He, Y; Huang, S; Liu, W; Wu, F; Zhang, Y; Zhu, N, 2013)
"Salvianolic acid B (Sal B) is a major water soluble component extracted from Radix Salviae miltiorrhizae, a traditional Chinese herb widely used for treating cardiovascular and hepatic diseases."	1.39	Salvianolic acid B inhibits hepatic stellate cell activation through transforming growth factor beta-1 signal transduction pathway in vivo and in vitro. ( Fu, WW; Liu, CH; Shen, L; Tao, YY; Wang, QL, 2013)
"Thus, using HGF in gene therapy against liver fibrosis is an attractive approach."	1.39	Efficacy of HGF carried by ultrasound microbubble-cationic nano-liposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. ( Li, WY; Wen, KM; Wu, W; Zhang, SH; Zhao, JN, 2013)
"Praziquantel (PZQ) is an isoquinoline derivative (2-cyclohexylcarbonyl-1, 2, 3, 6, 7, 11b-hexahydro-4H-pyrazino{2,1-a}-isoquinoline-4-one), and is currently the drug of choice for all forms of schistosomiasis."	1.38	Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. ( Ain-Shoka, AA; Badawy, AA; Ebeid, FA; El-Lakkany, NM; El-Maadawy, WH; Hammam, OA, 2012)
"(Betulaceae)."	1.38	The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-κB nuclear protein translocation. ( Bai, T; Li, Q; Li, X; Lian, LH; Nan, JX; Ouyang, BQ; Wan, Y; Wu, YL; Xie, WX; Yang, N, 2012)
"A CCl(4)-induced liver fibrosis model in mice was also utilized."	1.38	C/EBP-α ameliorates CCl(4)-induced liver fibrosis in mice through promoting apoptosis of hepatic stellate cells with little apoptotic effect on hepatocytes in vitro and in vivo. ( Chen, Q; Cheng, YY; Deng, L; Ding, D; Li, QQ; Liu, XP; Mei, S; Ou-Yang, Q; Tao, LL; Xu, JW; Xu, ZD; Yu, J, 2012)
"The rat model of liver fibrosis was induced by subcutaneous injection of 40% (v/v) of CCl₄ diluted in olive oil (3 mL/kg body weight) twice per week for 8 weeks."	1.38	Polyprenols from Taxus chinensis var. mairei prevent the development of CCl₄-induced liver fibrosis in rats. ( Fu, C; Liu, B; Qian, H; Wang, Y; Yu, J; Zhao, Y, 2012)
"Molecular MRI of liver fibrosis with a collagen-specific probe identifies fibrotic tissue in two rodent models of disease."	1.38	Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. ( Alford, JK; Caravan, P; Fuchs, BC; Guimaraes, AR; Lauwers, GY; Loving, GS; Polasek, M; Schühle, DT; Tanabe, KK; Uppal, R; Wei, L; Yamada, S, 2012)
"Cholestatic liver fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) proteins, is associated with bile acid-induced oxidative stress and lipid peroxidation."	1.38	Aqueous extract of Artemisia iwayomogi Kitamura attenuates cholestatic liver fibrosis in a rat model of bile duct ligation. ( Choi, MK; Han, JM; Hwang, SY; Kim, HG; Lee, JS; Park, HJ; Son, CG; Son, SW; Wang, JH, 2012)
"The hydroxyproline (HYP) content was detected by acid hydrolysis method."	1.38	[Comparison of effect of formulas clearing away heat and promoting blood circulation on prevention and treatment of liver fibrosis in CCl4 mice]. ( Liu, C; Liu, P; Peng, Y; Ren, H; Tao, Y; Wang, Z; Yu, H; Zhao, Z; Zhu, B, 2012)
"PF administration attenuated DMN-induced liver fibrosis at least in part by regulating macrophage disruption in the main organs."	1.38	Paeoniflorin regulates macrophage activation in dimethylnitrosamine-induced liver fibrosis in rats. ( Chen, X; Liu, C; Lu, L; Lu, Y; Lv, Z; Pan, Q; Xu, Q; Yang, Z, 2012)
"Induction of liver fibrosis was produced in male Swiss mice by subcutaneous injection of S."	1.37	Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice. ( El-Agamy, DS; Said, SA; Shebl, AM, 2011)
"Liver fibrosis was induced by intraperitoneal injection of 200 mg/kg body weight."	1.37	Hepatoprotective activity of a phytotherapeutic formula on thioacetamide--induced liver fibrosis model. ( Catanzaro, R; Jains, S; Kantah, MK; Kobayashi, R; Marotta, F; Minelli, E; Naito, Y; Polimeni, A; Solimene, U; Sollano, J, 2011)
"Liver fibrosis was induced by the oral administration of 20% carbon tetrachloride (CCl(4)), twice weekly and for 8 weeks."	1.36	Ameliorative effects of Moringa oleifera Lam seed extract on liver fibrosis in rats. ( Hamza, AA, 2010)
"Baicalein treatment (20, 40, or 80 mg/kg for 10 weeks) dose-dependently decreased levels of these markers."	1.36	Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. ( Che, QM; Pu, XP; Sun, H; Zhao, X, 2010)
"Coffee exerts protective effects against liver fibrosis via antioxidant action and the suppression of fibrogenic cytokines, TGF-beta and PDGF-beta."	1.36	Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. ( Kang, JK; Shin, JW; Son, CG; Wang, JH, 2010)
"To induce liver fibrosis, C57BL6 female mice were injected i."	1.35	Platelets contribute to the reduction of liver fibrosis in mice. ( Aoyagi, Y; Fukunaga, K; Hashimoto, I; Ikeda, O; Matsuo, R; Murata, S; Nakano, Y; Ohkohchi, N; Watanabe, M; Yasue, H, 2009)
"Carbon tetrachloride (CCl(4)) was given orally to rats twice a week for 8 weeks."	1.35	Lipid peroxidation products do not activate hepatic stellate cells. ( Fang, HL; Lin, WC, 2008)
"In both acute hepatotoxicity and liver fibrosis, serum aminotransferase levels and lipid peroxidation were increased and the hepatic glutathione content was decreased."	1.35	Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fibrosis. ( Cheon, HJ; Kim, SH; Lee, SM; Oh, ST; Shim, KS; Shin, E; Yun, N, 2009)
"Praziquantel treatment in Opisthorchis viverrini-infected patients reduces the hepatobiliary fibrosis due to tissue resorption, however, some fibroses are irreversible."	1.35	Effect of praziquantel treatment on the expression of matrix metalloproteinases in relation to tissue resorption during fibrosis in hamsters with acute and chronic Opisthorchis viverrini infection. ( Boonmars, T; Hiraku, Y; Pinlaor, P; Pinlaor, S; Prakobwong, S; Wongkham, C, 2009)
"Liver fibrosis was induced by PS injection (0."	1.35	Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells. ( Li, X; Liu, H; Sun, WY; Wei, W, 2009)
"Luteolin treatment has increased hepatic matrix metalloproteinase-9 levels and metallothionein (MT) I/II expression, eliminated fibrinous deposits and restored architecture of the liver in a dose-dependent manner."	1.35	Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. ( Domitrović, R; Jakovac, H; Sain, I; Tomac, J, 2009)
"Treatment of liver fibrosis associated with Schistosoma japonicum ova-induced granulomas remains a challenging proposition."	1.35	Paeoniflorin: a monomer from traditional Chinese medical herb ameliorates Schistosoma japonicum egg-induced hepatic fibrosis in mice. ( Li, X; Luo, Q; Shen, J; Wei, W; Wen, H; Zhong, Z, 2009)
"Enalapril was significantly more effective than captopril (p<0."	1.35	Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats. ( Ghazi-Khansari, M; Ghobadi, G; Karimian, G; Mohammadi-Karakani, A; Shakiba, B; Sotoudeh, M, 2008)
"CCl4-induced liver fibrosis in rats was not aggravated by corn oil treatment."	1.35	Corn oil enhancing hepatic lipid peroxidation induced by CCl4 does not aggravate liver fibrosis in rats. ( Fang, HL; Lin, WC, 2008)
" In conclusion, long-term administration of YCHT in rats ameliorated the hydropholic bile acids induced hepatic injury that probably related to a reduced oxidant stress and degree of hepatic fibrosis."	1.34	Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats. ( Chang, HH; Chen, JH; Hsueh, ML; Kuo, JJ; Lee, TY, 2007)
"Liver fibrosis was also induced by the injection of NaAsO(2)."	1.34	Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis. ( Basu, MK; Chakrabarti, RN; Das, N; Das, S; Mandal, AK, 2007)
"Rat liver cirrhosis was achieved by IP injection of carbon tetrachloride (CCl4) three times weekly for 8 weeks."	1.34	Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. ( Luo, HS; Lv, P; Paul, SC; Si, XM; Xiao, YJ; Zhou, XP; Zhou, YH, 2007)
"Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver that may evolve into fibrosis or cirrhosis."	1.34	Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. ( Accatino, L; Aguayo, G; Arrese, M; Duarte, I; Ibañez, P; Miquel, JF; Pizarro, M; Solis, N, 2007)
"Cystamine can ameliorate CCl(4) induced liver fibrosis and protect hepatic function."	1.34	Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. ( Chen, W; Qiu, JF; Wu, ZY; Zhang, ZQ, 2007)
"Using dimethylnitrosamine-induced liver cirrhosis animal, POMU even at 20 mg/(kg day) dosage, was illustrated to reverse the pathogenic progression of the disease, decrease the hydroxyproline content and increases the expression of HGF messenger RNA in liver tissue."	1.34	Chinese herb Radix Polygoni Multiflori as a therapeutic drug for liver cirrhosis in mice. ( Chen, CF; Horng, LY; Huang, CH; Wu, RT, 2007)
"Both alcohol and protein deficiency lead to reduced bone formation."	1.33	Effect of zinc supplementation on ethanol-mediated bone alterations. ( De la Vega-Prieto, MJ; Durán-Castellón, MC; García-Valdecasas Campelo, E; González-Reimers, E; López-Lirola, A; Martín-Olivera, R; Pérez-Ramírez, A; Santolaria-Fernández, F, 2005)
"The extent of liver fibrosis was assessed by measuring the level of liver hydroxy proline (HP) and serum enzyme levels."	1.33	Inhibition of CCl4-induced liver fibrosis by Piper longum Linn.? ( Chidambaranathan, N; Christina, AJ; Kothai, R; Nalini, G; Robert, SJ; Saraswathy, GR; Therasal, RL, 2006)
"CCl(4) caused liver fibrosis, featuring increased prothrombin time, hepatic MDA and HP contents, and spleen weight and decreased plasma albumin level."	1.33	Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats. ( Fang, HL; Kuo, SC; Lin, WC; Lin, WL; Wang, BC, 2006)
"CP exerts rather good action against liver fibrosis, and with the mechanism relating to improve degradation of the deposited collagens and anti-lipid peroxiation."	1.33	[Effects of corydyceps polysaccharide on liver fibrosis induced by DMN in rats]. ( Li, FH; Liu, P; Xiong, WG; Xu, GF, 2006)
"The hydroxyproline content was significantly higher in the control groups than in the DMN+LSKL group."	1.32	A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. ( Etani, Y; Kondou, H; Michigami, T; Miyoshi, Y; Mushiake, S; Ozono, K, 2003)
"Schistosomiasis mansoni is a tropical helminthic disease characterized by parasite egg-induced granulomatous inflammation and cumulative fibrosis."	1.32	Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. ( Boros, DL; Gerard, HC; Hudson, AP; Singh, KP, 2004)
"Melatonin is a potent physiological scavenger of hydroxyl radicals."	1.32	Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. ( Aydin, S; Aytekin, H; Canbakan, B; Mert, A; Ozaras, R; Ozbay, G; Senturk, H; Tahan, V; Uzun, H; Yildirim, B, 2004)
"Liver cirrhosis is caused by a relative imbalance between synthesis and degradation of collagens."	1.32	Arg-Gly-Asp (RGD) peptide ameliorates carbon tetrachloride-induced liver fibrosis via inhibition of collagen production and acceleration of collagenase activity. ( Enjoji, M; Fukushima, M; Kobayashi, N; Kohjima, M; Kotoh, K; Morizono, S; Nakamuta, M; Nawata, H, 2004)
" The aim of this study was to evaluate the effect of Pirfenidone in the reversion or prevention of cirrhosis experimentally induced in rats by chronic administration of CCl(4) and bile-duct ligation (BDL)."	1.31	Pirfenidone effectively reverses experimental liver fibrosis. ( Armendariz-Borunda, J; Garcia, J; García, L; Grijalva, G; Hernández, I; Margolin, S; Muriel, P; Salazar, A; Sandoval, A; Vera, J, 2002)
"Liver fibrosis was induced in male Sprague-Dawley rats by bile duct ligation and scission (BDL)."	1.31	Anti-fibrotic effects of a hot-water extract from Salvia miltiorrhiza roots on liver fibrosis induced by biliary obstruction in rats. ( Kang, HC; Kim, JY; Nan, JX; Park, EJ; Park, PH; Sohn, DH, 2001)
"Liver cirrhosis was induced by CCl(4) inhalation and phenobarbital in Wistar rats."	1.31	Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. ( Castilla-Cortázar, I; García, M; Muguerza, B; Prieto, J; Quiroga, J; Santidrián, S, 2001)
"Pirfenidone has no major side effects in vivo."	1.31	Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. ( Enjoji, M; Iwamoto, H; Kato, M; Nakamuta, M; Nakashima, Y; Nawata, H; Sugimoto, R; Tada, S, 2001)
"Liver fibrosis was induced by a bile duct ligation and scission (BDL/S) operation, duration of 4 weeks in rats."	1.31	Antifibrotic effect of extracellular biopolymer from submerged mycelial cultures of Cordyceps militaris on liver fibrosis induced by bile duct ligation and scission in rats. ( Ko, G; Nan, JX; Park, EJ; Sohn, DH; Song, CH; Yang, BK, 2001)
"Liver fibrosis was induced by carbon tetrachloride (CCl4) in rats an d evaluated with plasma hyaluranic acid level and hepatic hydroxyproline content."	1.31	Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. ( Guo, C; Liu, FT; Xie, WF; Zhang, JP; Zhang, M; Zhou, B; Zhou, JP, 2001)
"Emodin has therapeutic effect on the development of hepatic fibrosis in rats."	1.31	[Effect of emodin on development of hepatic fibrosis in rats]. ( Li, D; Wei, H; Zhan, Y, 2000)
"Osteoporosis was considered as a factor in spinal bone mineral density with a Z-score below 2 or at least one vertebral fracture."	1.30	Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. ( Guañabens, N; Martinez de Osaba, MJ; Monegal, A; Muñoz-Gómez, J; Navasa, M; Peris, P; Pons, F; Rimola, A; Rodés, J, 1997)
"Splenectomy might delay the progress of liver fibrosis for about 3 weeks."	1.30	Effect of splenectomy on CCl4-induced liver fibrosis in rats. ( Chen, D; Leng, E; Liu, W; Wu, B, 1998)
"Treatment with oxamniquine resulted in near total eradication of S."	1.28	Evaluation of hepatic fibrosis after oxamniquine therapy of murine schistosomiasis. ( Girgis, NI; Ishak, EA; Khayyal, MT; Mansour, MM; Morcos, SH; Saleh, S, 1992)
"However, the patients with alcoholic liver cirrhosis had proline and hydroxyproline values significantly higher than the normal group."	1.25	Serum free proline and free hydroxyproline in patients with chronic liver disease. ( Kershenobich, D; Mata, JM; Rojkind, M; Villarreal, E, 1975)

Timeframe	Studies, this research(%)	All Research%
pre-1990	72 (25.71)	18.7374
1990's	8 (2.86)	18.2507
2000's	77 (27.50)	29.6817
2010's	107 (38.21)	24.3611
2020's	16 (5.71)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension[NCT01282385]			Phase 4	60 participants (Anticipated)	Interventional	2011-04-30	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
[Techniques for studying collagen in medical practice]. Annales de biologie clinique, 1982, Volume: 40, Issue:5 Topics: Animals; Antibodies; Bone Diseases; Chemical Phenomena; Chemistry; Collagen; Diagnosis, Differential	1982
Possible modification of scar tissue by biochemical methods. Equine veterinary journal, 1979, Volume: 11, Issue:2 Topics: Aminopropionitrile; Animals; Cicatrix; Collagen; Cortisone; Humans; Hydroxylysine; Hydroxyproline; L	1979

Article	Year
[Clinical and experimental study on anti-liver fibrosis effect of xuelong granule]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2001, Volume: 21, Issue:11 Topics: Adult; Aged; Animals; Drugs, Chinese Herbal; Female; Hepatitis B; Humans; Hyaluronic Acid; Hydroxypr	2001
Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis. World journal of gastroenterology, 2001, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents; Biopsy; Carbon Tetrachloride; Dimethylnitrosamine; Disease Models, A	2001

hydroxyproline and Cirrhosis, Liver

Research Excerpts

Research

Studies (280)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Kim, AD	1
Kim, SE	1
Leszczynska, A	1
Kaufmann, B	1
Reca, A	1
Kim, DJ	1
Feldstein, AE	1
Abdel-Rahman, RF	1
Fayed, HM	1
Asaad, GF	1
Ogaly, HA	1
Hessin, AF	1
Salama, AAA	2
Abd El-Rahman, SS	1
Arbid, MS	1
Mohamed, MAE	1
Bai, L	1
Wang, YL	1
Chen, YL	1
Li, HX	1
Zhu, SW	1
Liu, Y	2
Song, ZC	1
Duan, SZ	1
Hernández-Bustabad, A	1
Morales-Arraez, D	1
González-Paredes, FJ	1
Abrante, B	1
Díaz-Flores, F	1
Abreu-González, P	1
de la Barreda, R	1
Quintero, E	1
Hernández-Guerra, M	1
Serdjebi, C	1
Bertotti, K	1
Huang, P	1
Wei, G	1
Skelton-Badlani, D	1
Leclercq, IA	1
Barbes, D	1
Lepoivre, B	1
Popov, YV	1
Julé, Y	1
Takano, M	1
Watanabe, H	1
Toda, S	1
Nishida, K	1
Imafuku, T	1
Minayoshi, Y	1
Nakano, T	1
Maeda, H	1
Maruyama, T	1
Wang, S	1
Ye, F	1
Ren, Q	1
Sun, S	1
Xia, W	1
Wang, Z	5
Guo, H	1
Li, H	3
Zhang, S	2
Lowe, S	1
Chen, M	1
Du, Q	1
Elfeky, MG	1
Mantawy, EM	1
Gad, AM	1
Fawzy, HM	1
El-Demerdash, E	3
Geng, W	1
Zhou, G	2
Zhao, B	1
Xiao, Q	1
Li, C	1
Fan, S	1
Dong, P	2
Zheng, J	2
Ye, HL	1
Zhang, JW	1
Chen, XZ	1
Wu, PB	1
Chen, L	2
Zhang, G	1
Hartimath, SV	1
Boominathan, R	1
Soh, V	1
Cheng, P	1
Deng, X	1
Chong, YC	1
Yong, FF	1
Tan, PW	1
Han, W	1
Robins, EG	1
Goggi, JL	1
Gutierrez-Herrera, E	1
Sánchez-Pérez, C	1
Perez-Garcia, A	1
Padilla-Castaneda, MA	1
Franco, W	1
Hernández-Ruiz, J	1
Li, G	2
Zhang, J	5
Jiang, Q	1
Liu, B	2
Xu, K	1
Leslie, J	1
Macia, MG	1
Luli, S	1
Worrell, JC	1
Reilly, WJ	1
Paish, HL	1
Knox, A	1
Barksby, BS	1
Gee, LM	1
Zaki, MYW	1
Collins, AL	1
Burgoyne, RA	1
Cameron, R	1
Bragg, C	1
Xu, X	1
Chung, GW	1
Brown, CDA	1
Blanchard, AD	1
Nanthakumar, CB	1
Karsdal, M	1
Robinson, SM	1
Manas, DM	1
Sen, G	1
French, J	1
White, SA	1
Murphy, S	1
Trost, M	1
Zakrzewski, JL	1
Klein, U	1
Schwabe, RF	1
Mederacke, I	1
Nixon, C	1
Bird, T	1
Teuwen, LA	1
Schoonjans, L	1
Carmeliet, P	1
Mann, J	1
Fisher, AJ	1
Sheerin, NS	1
Borthwick, LA	1
Mann, DA	1
Oakley, F	1
Lee, PC	1
Hsieh, YC	1
Huo, TI	1
Yang, UC	1
Lin, CH	1
Li, CP	1
Huang, YH	2
Hou, MC	1
Lin, HC	1
Lee, KC	1
Liang, J	1
Yuan, H	1
Xu, L	4
Wang, F	2
Bao, X	1
Yan, Y	1
Wang, H	5
Zhang, C	1
Jin, R	1
Ma, L	2
Huri, L	1
Su, X	2
Xiao, R	1
Ma, Y	1
Gabr, SA	1
Alghadir, AH	1
El-Sisi, AEE	1
Sokar, SS	1
Shebl, AM	2
Mohamed, DZ	1
Tian, X	2
Zhao, C	1
Guo, J	1
Xie, S	1
Yin, F	1
Huo, X	1
Zhang, X	1
Elhenawy, AA	1
Ashour, RH	1
Nabih, N	1
Shalaby, NM	1
Megahed, N	1
Mortezaee, K	1
Khanlarkhani, N	1
Sabbaghziarani, F	1
Nekoonam, S	1
Majidpoor, J	1
Hosseini, A	1
Pasbakhsh, P	1
Kashani, IR	1
Zendedel, A	1
Zhang, Y	7
Zhao, H	1
Cao, W	1
Zhang, T	1
Wang, SW	1
Bashandy, SAE	1
Alaamer, A	1
Moussa, SAA	1
Omara, EA	1
Shin, SK	1
Kwon, OS	2
Lee, JJ	1
Park, YH	1
Choi, CS	1
Jeong, SH	1
Choi, DJ	1
Kim, YS	1
Kim, JH	1
Lebda, MA	1
Sadek, KM	1
Abouzed, TK	1
Tohamy, HG	1
El-Sayed, YS	1
Heidari, R	1
Ghanbarinejad, V	1
Mohammadi, H	1
Ahmadi, A	1
Esfandiari, A	1
Azarpira, N	1
Niknahad, H	1
Yan, H	1
Huang, Z	1
Bai, Q	1
Sheng, Y	1
Hao, Z	1
Ji, L	2
Saber, S	1
Mahmoud, AAA	1
Helal, NS	1
El-Ahwany, E	1
Abdelghany, RH	1
Dhar, A	1
Sadiq, F	1
Anstee, QM	1
Levene, AP	1
Goldin, RD	1
Thursz, MR	1
Guo, T	1
Liu, ZL	2
Zhao, Q	1
Zhao, ZM	1
Liu, CH	4
Mansour, HM	1
Abdel-Salam, RM	1
Ahmed, NA	1
Yassen, NN	1
Zaki, HF	1
Miao, H	2
Guan, H	1
Wang, C	2
Ma, J	2
Qiu, Y	1
Wang, M	2
Zhang, M	2
Zhao, X	2
Jiang, H	3
Guo, C	2
He, Q	1
Liang, T	1
Duan, X	2
Li, R	1
Hara, M	1
Kono, H	1
Furuya, S	1
Hirayama, K	1
Tsuchiya, M	3
Fujii, H	1
Xie, Y	1
Gao, Y	2
Yuan, J	1
Li, J	5
Wang, J	4
Li, L	2
Chu, L	1
Yao, Q	1
Lin, Y	2
Li, X	8
Shen, X	1
Tu, C	1
Wu, F	1
Huang, S	1
Zhu, N	1
Liu, W	2
He, Y	1
Chen, X	4
Ying, X	1
Zhang, W	2
Chen, Y	4
Shi, C	2
Hou, Y	1
Tao, YY	2
Wang, QL	1
Shen, L	2
Fu, WW	2
Zhang, SH	1
Wen, KM	1
Wu, W	1
Li, WY	1
Zhao, JN	1
Wang, Y	4
Yang, X	1
Yu, R	1
Zheng, C	1
Said, E	1
Said, SA	2
Gameil, NM	1
Ammar, EM	1
Huang, X	1
Wang, X	5
Lv, Y	1
Lin, J	1
Diao, Y	1
Heeba, GH	1
Mahmoud, ME	1
Qian, H	2
Shi, J	1
Fan, TT	1
Lv, J	1
Chen, SW	1
Song, CY	1
Zheng, ZW	1
Xie, WF	2
Chen, YX	1
Reiter, R	1
Freise, C	1
Jöhrens, K	1
Kamphues, C	1
Seehofer, D	1
Stockmann, M	1
Somasundaram, R	1
Asbach, P	1
Braun, J	1
Samani, A	1
Sack, I	1
Tung, YT	1
Tang, TY	1
Chen, HL	1
Yang, SH	1
Chong, KY	1
Cheng, WT	2
Chen, CM	1
Yao, Y	1
Zhou, C	1
Chu, D	1
Qiu, B	1
Wei, F	1
Sun, X	2
Duan, B	1
Qiu, W	1
Mu, W	1
Jobara, K	1
Kaido, T	1
Hori, T	1
Iwaisako, K	1
Endo, K	1
Uchida, Y	1
Uemoto, S	1
Peng, SY	1
Chou, CJ	1
Cheng, PJ	1
Ko, IC	1
Kao, YJ	1
Chen, YH	1
Shaw, SW	1
Wu, SC	1
Wang, YH	1
Zhao, CX	1
Chen, BM	1
He, M	2
Liu, LQ	1
Li, CY	1
Shkurupii, VA	1
Kim, LB	1
Potapova, OV	1
Sharkova, TV	1
Putyatina, AN	1
Nikonova, IK	1
Iskra, NI	1
Hur'iev, SO	1
Shatrova, KM	1
Roshchin, HH	1
Kuz'min, VIu	1
He, C	1
Wu, WY	1
Huang, H	1
Li, WZ	1
Yin, YY	2
Yan, XC	1
Zhou, T	1
Hayashizaki-Someya, Y	1
Kurosaki, E	1
Takasu, T	1
Mitori, H	1
Yamazaki, S	1
Koide, K	1
Takakura, S	1
Li, Y	2
Wang, W	1
Jia, X	1
Zhai, S	1
Dang, S	1
Harris, TR	1
Bettaieb, A	1
Kodani, S	1
Dong, H	1
Myers, R	1
Chiamvimonvat, N	1
Haj, FG	1
Hammock, BD	1
Buko, V	1
Belonovskaya, E	1
Naruta, E	1
Lukivskaya, O	1
Kanyuka, O	1
Zhuk, O	1
Kranc, R	1
Stoika, R	1
Sybirna, N	1
Du, Y	1
Li, LN	1
Fang, BW	2
Dong, D	1
Yin, L	1
Qi, Y	1
Peng, J	2
Hussein, RM	1
Elsirafy, OM	1
Wahba, YS	1
Kawy, HS	1
Hasanin, AH	1
Hamam, GG	1
He, W	1
Zhuang, Y	1
Wang, L	2
Qi, L	1
Chen, B	1
Shao, D	1
Chen, J	1
Zhou, YN	1
Mu, YP	1
Ning, BB	1
Du, GL	1
Chen, JM	1
Sun, MY	1
Zhang, H	1
Hu, YY	1
Xu, LM	1
Liu, P	3
Mao, Y	1
Chen, S	1
Wu, X	1
Lu, Z	1
Yu, F	1
Liu, C	3
Yang, Z	2
Lu, Y	2
Tang, B	1
Xu, Q	2
Xu, P	1
Yuan, Q	2
Song, L	1
Liu, M	1
Liu, Z	1
Yang, Y	1
Li, D	2
Ren, G	1
Moczydlowska, J	1
Miltyk, W	1
Hermanowicz, A	1
Lebensztejn, DM	1
Palka, JA	1
Debek, W	1
Kim, HJ	1
Cho, YA	1
Lee, YM	1
Lee, SY	1
Bae, WJ	1
Kim, EC	1
Zhan, YY	1
Wang, JH	5
Feng, SX	1
Xue, L	1
Tian, LP	1
Cheng, Y	1
Mai, JY	1
Wang, MF	1
Chen, GF	1
Ping, J	2
Ganai, AA	1
Ganaie, IA	1
Verma, N	1
Farooqi, H	1
Liu, F	1
Rao, HY	1
Teng, X	1
Ren, YY	2
Lu, YQ	1
Wu, N	1
Liu, FF	1
Wei, L	3
Abdel-Sattar, SA	1
El-Bakly, WM	1
Mohamed, EA	1
Kim, YO	1
Popov, Y	1
Schuppan, D	1
Hsieh, CC	1
Fang, HL	6
Lina, WC	1
Watanabe, M	1
Murata, S	1
Hashimoto, I	1
Nakano, Y	1
Ikeda, O	1
Aoyagi, Y	1
Matsuo, R	1
Fukunaga, K	1
Yasue, H	1
Ohkohchi, N	1
Lin, WC	6
Yuan, LP	1
Chen, FH	1
Ling, L	1
Bo, H	1
Chen, ZW	1
Li, F	1
Zhong, MM	1
Xia, LJ	1
Lai, JT	1
Kim, SH	1
Cheon, HJ	1
Yun, N	1
Oh, ST	1
Shin, E	1
Shim, KS	1
Lee, SM	2
Prakobwong, S	3
Pinlaor, S	3
Yongvanit, P	2
Sithithaworn, P	1
Pairojkul, C	1
Hiraku, Y	3
Hong, RT	1
Xu, JM	1
Mei, Q	1
Lubel, JS	1
Herath, CB	1
Tchongue, J	2
Grace, J	1
Jia, Z	1
Spencer, K	1
Casley, D	1
Crowley, P	1
Sievert, W	2
Burrell, LM	1
Angus, PW	1
Bennett, RG	1
Heimann, DG	1
Tuma, DJ	1
Boonmars, T	1
Wongkham, C	1
Pinlaor, P	2
Liu, H	1
Wei, W	3
Sun, WY	1
Xu, W	2
Wang, LW	1
Shi, JZ	1
Gong, ZJ	3
Deng, ZY	1
Jin, Y	1
Chen, XL	1
Lü, XW	1
Wu, YW	1
Oh, SW	1
Kim, DH	1
Ha, JR	1
Kim, DY	1
Domitrović, R	1
Jakovac, H	1
Tomac, J	1
Sain, I	1
Kemp, W	1
Kompa, A	1
Phrommintikul, A	1
Herath, C	1
Zhiyuan, J	1
Angus, P	1
McLean, C	1
Roberts, S	1
Krum, H	1
Hamza, AA	1
Kim, HK	1
Yang, TH	1
Cho, HY	1
Fang, B	1
Luo, S	1
Song, Y	1
Li, N	1
Zhao, RC	1
Yu, Y	1
Lu, L	2
Qian, X	1
Chen, N	1
Yao, A	1
Pu, L	1
Zhang, F	1
Kong, L	1
Sun, B	1
Sun, H	1
Che, QM	1
Pu, XP	1
Yang, FR	1
Lou, JS	1
Shin, JW	3
Kang, JK	1
Son, CG	4
Wu, JB	1
Chuang, HR	1
Yang, LC	1
Laothong, U	1
Matono, T	1
Koda, M	1
Tokunaga, S	1
Sugihara, T	1
Ueki, M	1
Murawaki, Y	2
Hessien, MH	1
El-Sharkawi, IM	1
El-Barbary, AA	1
El-Beltagy, DM	1
Snyder, N	1
Itoh, A	1
Isoda, K	1
Kondoh, M	1
Kawase, M	1
Watari, A	1
Kobayashi, M	1
Tamesada, M	1
Yagi, K	1
Hsu, CL	1
Hsu, CC	1
Yen, GC	1
Ouyang, J	2
Gao, Z	1
Ren, Z	2
Hong, D	1
Qiao, H	3
Liu, TH	1
You, H	1
Xu, YQ	1
Shen, J	1
Zhong, Z	1
Wen, H	1
Luo, Q	1
Gu, K	1
Zhao, JD	1
Ren, ZG	1
Ma, NY	1
Lai, ST	1
Liu, J	1
Jiang, GL	1
Hou, J	1
Tian, J	1
Jiang, W	2
Fu, F	1
Surya Narayanan, B	1
Latha, P	1
Rukkumani, R	1
Xu, JP	1
Zheng, YC	1
Chen, W	2
Sun, YW	1
Wu, ZY	2
Luo, M	1
Tong, Y	1
Han, H	1
Tian, XP	1
Liang, YJ	1
Luo, J	1
Zheng, D	1
Liu, YP	1
Shi, L	1
Zhou, Y	1
Chen, AL	1
Sun, KY	1
Sun, Y	1
Zhang, ZS	1
Joshi, PP	1
Patil, SD	1
Silawat, N	1
Deshmukh, PT	1
Tomur, A	1
Kanter, M	1
Gurel, A	1
Erboga, M	1
Wang, T	1
Zhao, LJ	1
Li, P	1
Lu, GC	1
Zhang, WD	1
Li, HL	1
Yuan, BJ	1
Pieper-Fürst, U	1
Hall, R	1
Huss, S	1
Hochrath, K	1
Fischer, HP	1
Tacke, F	1
Weiskirchen, R	1
Lammert, F	1
El-Agamy, DS	1
Tan, G	1
Pan, S	1
Dong, X	1
Kang, K	1
Zhao, M	1
Jiang, X	1
Kanwar, JR	1
di Bonifácio, M	1
Parra, RS	1
Almeida, AL	1
Rocha, JJ	1
Feres, O	1
Kantah, MK	1
Kobayashi, R	1
Sollano, J	1
Naito, Y	1
Solimene, U	1
Jains, S	1
Catanzaro, R	1
Minelli, E	1
Polimeni, A	1
Marotta, F	1
Knight, V	1
Lourensz, D	1
Tipping, P	1
Kang, JW	1
Yoon, SJ	1
Sung, YK	1
El-Lakkany, NM	1
Hammam, OA	1
El-Maadawy, WH	1
Badawy, AA	1
Ain-Shoka, AA	1
Ebeid, FA	1
Choi, MK	2
Hwang, SY	2
Wan, Y	1
Wu, YL	1
Lian, LH	1
Xie, WX	1
Ouyang, BQ	1
Bai, T	1
Li, Q	1
Yang, N	1
Nan, JX	4
Tao, LL	1
Cheng, YY	1
Ding, D	1
Mei, S	1
Xu, JW	1
Yu, J	2
Ou-Yang, Q	1
Deng, L	1
Chen, Q	1
Li, QQ	1
Xu, ZD	1
Liu, XP	1
Zhao, Y	1
Fu, C	1
Polasek, M	1
Fuchs, BC	1
Uppal, R	1
Schühle, DT	1
Alford, JK	1
Loving, GS	1
Yamada, S	3
Lauwers, GY	1
Guimaraes, AR	1
Tanabe, KK	1
Caravan, P	1
Feng, Q	1
Fu, Q	1
Hu, Y	1
Han, JM	1
Kim, HG	1
Lee, JS	2
Park, HJ	1
Son, SW	1
Hao, ZM	1
Cai, M	1
Lv, YF	1
Li, HH	1
Tzeng, JI	1
Chen, MF	1
Chung, HH	1
Cheng, JT	1
Huang, Q	2
Huang, R	1
Zheng, L	1
Liao, M	1
Zhuo, L	1
Lin, X	1
Zhao, Z	1
Yu, H	1
Peng, Y	2
Ren, H	1
Tao, Y	1
Zhu, B	1
Hung, GD	1
Li, PC	1
Lee, HS	2
Chang, HM	1
Chien, CT	1
Lee, KL	1
Lv, Z	1
Pan, Q	1
Yoshiji, H	1
Kuriyama, S	1
Yoshii, J	1
Ikenaka, Y	1
Noguchi, R	1
Nakatani, T	1
Tsujinoue, H	1
Yanase, K	1
Namisaki, T	1
Imazu, H	1
Fukui, H	1
García, L	1
Hernández, I	1
Sandoval, A	1
Salazar, A	1
Garcia, J	1
Vera, J	1
Grijalva, G	1
Muriel, P	1
Margolin, S	1
Armendariz-Borunda, J	1
Li, ZZ	1
Sui, ZY	1
Bychkova, VI	1
Smirnov, BM	2
Lesnichuk, LV	1
Sakaida, I	2
Kawaguchi, K	1
Kimura, T	1
Terai, S	1
Okita, K	2
KAMOCHI, D	1
ARNOLD, H	1
DELBRUECK, A	1
HARTMANN, F	1
TANAKA, T	1
ITURRIAGA, H	1
PIZZI, T	1
UGARTE, G	1
LORCA, F	1
KENT, G	1
VOLINI, FI	1
MINICK, OT	1
ORFEI, E	1
DELAHUERGA, J	1
HUTTERER, F	1
RUBIN, E	1
POPPER, H	2
Kondou, H	1
Mushiake, S	1
Etani, Y	1
Miyoshi, Y	1
Michigami, T	1
Ozono, K	1
Singh, KP	2
Gerard, HC	2
Hudson, AP	2
Boros, DL	2
Yuan, GJ	1
Zhang, ML	1
Xu, J	1
Lee, G	1
Vierling, JM	1
Maher, JJ	1
Yang, CQ	1
Liu, WB	1
Wang, YQ	1
He, BM	1
Wang, JY	2
Ochi, T	1
Kawakita, T	1
Nomoto, K	1
Tahan, V	1
Ozaras, R	1
Canbakan, B	1
Uzun, H	1
Aydin, S	1
Yildirim, B	1
Aytekin, H	1
Ozbay, G	1
Mert, A	1
Senturk, H	1
Kotoh, K	1
Nakamuta, M	3
Kohjima, M	1
Fukushima, M	1
Morizono, S	1
Kobayashi, N	1
Enjoji, M	3
Nawata, H	3
Geng, XX	2
Yang, Q	2
Xie, RJ	2
Luo, XH	2
Li, CX	2
Cheng, ML	2
Han, B	1
Jin, H	1
Wang, NP	1
Wu, CY	1
Yan, SX	1
Yue, L	1
Zhang, LL	1
Xu, SY	1
Müller, V	1
Brummer, D	1
Erhardt, W	1
Henke, J	1
Kissler, H	1
Bauer, M	1
Amann, K	1
Ott, R	1
Hohenberger, W	1
White, SL	1
Cutroneo, KR	1
Shun, CT	1
Chiou, LL	1
Chen, CH	1
Huang, GT	1
Sheu, JC	1
González-Reimers, E	1
Durán-Castellón, MC	1
Martín-Olivera, R	1
López-Lirola, A	1
Santolaria-Fernández, F	1
De la Vega-Prieto, MJ	1
Pérez-Ramírez, A	1
García-Valdecasas Campelo, E	1
Christina, AJ	1
Saraswathy, GR	1
Robert, SJ	1
Kothai, R	1
Chidambaranathan, N	1
Nalini, G	1
Therasal, RL	1
Hrckova, G	1
Velebný, S	1
Daxnerová, Z	1
Solár, P	1
Kuo, SC	1
Lin, WL	1
Wang, BC	1
Nabeshima, Y	1
Tazuma, S	1
Kanno, K	1
Hyogo, H	1
Iwai, M	1
Horiuchi, M	1
Chayama, K	1
Yang, L	1
Chan, CC	1
Liu, S	1
McGhee, J	1
Stimpson, SA	1
Chen, LZ	1
Harrington, WW	1
Symonds, WT	1
Rockey, DC	1
Lee, TY	1
Chang, HH	1
Chen, JH	1
Hsueh, ML	1
Kuo, JJ	1
Son, JY	1
Oh, SM	1
Han, SH	1
Cho, JH	1
Cho, CK	1
Yoo, HS	1
Lee, YW	1
Lee, MM	1
Hu, XP	1
Mandal, AK	1
Das, S	1
Basu, MK	1
Chakrabarti, RN	1
Das, N	1
Song, SL	1
Huang, YQ	1
Zhang, QR	1
Huang, TX	1
Lv, P	1
Luo, HS	1
Zhou, XP	1
Xiao, YJ	1
Paul, SC	1
Si, XM	1
Zhou, YH	1
Pereira, RM	1
Dos Santos, RA	1
Teixeira, MM	1
Leite, VH	1
Costa, LP	1
da Costa Dias, FL	1
Barcelos, LS	1
Collares, GB	1
Simões e Silva, AC	1
Xu, D	2
Wu, Y	1
Liao, ZX	1
Li, FH	1
Xiong, WG	1
Xu, GF	1
He, JY	1
Ge, WH	1
Du, SL	1
Pan, H	1
Lu, WY	1
Wu, J	1
Ibañez, P	1
Solis, N	1
Pizarro, M	1
Aguayo, G	1
Duarte, I	1
Miquel, JF	1
Accatino, L	1
Arrese, M	1
Trebicka, J	1
Hennenberg, M	1
Laleman, W	1
Shelest, N	1
Biecker, E	1
Schepke, M	1
Nevens, F	1
Sauerbruch, T	1
Heller, J	1
Qiu, JF	1
Zhang, ZQ	1
Huang, CH	1
Horng, LY	1
Chen, CF	1
Wu, RT	1
Salameh, N	1
Peeters, F	1
Sinkus, R	1
Abarca-Quinones, J	1
Annet, L	1
Ter Beek, LC	1
Leclercq, I	1
Van Beers, BE	1
Salam, OM	1
El-Batran, SA	1
Abdallah, HM	1
Shaffie, NM	1
Zhang, BJ	1
Guo, Y	1
Chen, LB	1
Karimian, G	1
Mohammadi-Karakani, A	1
Sotoudeh, M	1
Ghazi-Khansari, M	1
Ghobadi, G	1
Shakiba, B	1
Borel, JP	2
Caranjot, JM	1
Jayle, MF	1
Paterson, CR	1
Losowsky, MS	1
McPhie, JL	1
Maruyama, K	1
Feinman, L	1
Fainsilber, Z	1
Nakano, M	1
Okazaki, I	1
Lieber, CS	1
Okorokov, AN	1
Hirayama, C	4
Perier, C	1
Gautier, M	1
Baril, A	1
Bayle, JJ	1
Patouillard, G	1
Frey, J	1
Kosykh, AA	1
Solopaeva, IM	1
Volkova, AA	1
Maliugin, GV	1
Zmyzgova, AV	1
Fomina, TN	1
Iamshchikova, IG	1
Ballardini, G	1
Degli Esposti, S	1
Bianchi, FB	1
de Giorgi, LB	1
Faccani, A	1
Biolchini, L	1
Busachi, CA	1
Pisi, E	1
Zmudziński, J	1
Potkańska, A	1
Kapołka, D	1
Chociłowska, D	1
Malinowski, S	1
Gichev, IuP	2
Peskisheva, SF	1
D'Amore, M	1
Quarto, S	1
Lapadula, G	1
Bozzi, A	1
Carrozzo, M	1
Yuan, ZK	1
Guo, ZQ	1
Yang, YG	1
Monegal, A	1
Navasa, M	1
Guañabens, N	1
Peris, P	1
Pons, F	1
Martinez de Osaba, MJ	1
Rimola, A	1
Rodés, J	1
Muñoz-Gómez, J	1
Park, EJ	3
Kim, JY	2
Kang, HC	2
Choi, JH	1
Lee, SJ	1
Lee, BH	1
Kim, SJ	1
Lee, JH	1
Kim, YC	1
Sohn, DH	3
Chen, D	1
Leng, E	1
Wu, B	1
Park, PH	1
Abdallahi, OM	1
Bensalem, H	1
Diagana, M	1
De Reggi, M	1
Gharib, B	1
Tada, S	2
Iwamoto, H	2
Sugimoto, R	2
Nakashima, Y	2
Muguerza, B	1
Castilla-Cortázar, I	1
García, M	1
Quiroga, J	1
Santidrián, S	1
Prieto, J	1
Kato, M	1
Yang, BK	1
Song, CH	1
Ko, G	1
Bruck, R	1
Shirin, H	1
Aeed, H	1
Matas, Z	1
Hochman, A	1
Pines, M	1
Avni, Y	1
Zhang, JP	1
Zhou, JP	1
Liu, FT	1
Zhou, B	1
Gagliano, N	1
Arosio, B	1
Grizzi, F	1
Masson, S	1
Tagliabue, J	1
Dioguardi, N	1
Vergani, C	1
Annoni, G	1
Zhan, Y	1
Wei, H	1
Weng, HL	1
Cai, WM	1
Liu, RH	1
Yan, S	1
Deng, B	1
Hu, J	1
Anselmi, K	1
Subbotin, VM	1
Nemoto, E	1
Gandhi, CR	1
Kerwar, SS	1
Oronsky, AL	1
Choe, D	1
Alvarez, B	1
Mezey, E	1
Potter, JJ	1
Iber, FL	2
Maddrey, WC	1
Jackson, DS	1
Mansurov, KhKh	1
Mirodzhov, GK	1
Ladnaia, MM	1
Linchevskaia, AA	1
Khidirova, TA	1
Bretzke, G	1
List, A	1
Stahl, E	1
Kanta, J	1
Bartos, F	1
Henley, KS	1
Laughrey, EG	1
Appelman, HD	1
Flecker, K	1
Sakakibara, K	1
Umeda, M	1
Saito, S	1
Nagase, S	1
Zhivitsa, LV	1
Safonova, ES	1
Grasedyck, K	1
Lindner, J	1
Mata, JM	1
Kershenobich, D	1
Villarreal, E	1
Rojkind, M	2
Wu, A	1
Levi, AJ	1
Häkkinen, HM	1
Franssila, K	1
Kulonen, E	1
Morcos, SH	1
Mansour, MM	1
Khayyal, MT	1
Saleh, S	1
Ishak, EA	1
Girgis, NI	1
Trishkova, LA	1
Nawar, O	1
Akridge, RE	1
Hassan, E	1
el Gazar, R	1
Doughty, BL	1
Kemp, WM	1
Truckenbrodt, J	1
Müller, A	3
Kraul, H	1
Machnik, G	2
Volland, R	1
Reinhardt, M	1
Hoffmann, A	1
Aoto, Y	1
Suou, T	1
Machnik, F	1
Zimmermann, T	1
Schubert, H	1
Sitnikov, VA	1
Sharaev, PN	1
Walker, F	1
Shand, J	1
Murata, K	1
Okudaira, M	2
Akashio, K	1
Porta, EA	1
Kock, OR	1
Hartroft, WS	1
Kratzsch, KH	1
Becker, K	2
Galambos, JT	1
Shapira, R	1
Jordö, L	1
Olsson, R	3
Sasamoto, T	1
Kuehn, HA	1
Shiba, T	2
Kuzela, L	1
Horký, J	1
Resnick, RH	1
Cerda, JC	1
Boitnott, J	1
Aron, J	1
Kubo, S	1
Maros, T	1
Seres-Sturm, L	1
Lakatos, O	1
Seres-Sturm, MT	1
Blazsek, V	1
Ranek, L	1
Bremmelgaard, A	1
Dupont, B	1
Jorgensen, M	1
Keiding, S	1
Thomsen, P	1
Tyrsted, G	1
Kawabe, M	1
Morotomi, I	1
Kimura, N	1
Kaznacheev, VP	1
Korobkova, EN	1
Ruiz-Torres, A	1
Gerlach, U	1
Paul, L	1
Latzel, H	1
Boyett, JD	1
Sullivan, JF	1
Gertman, PM	1
Madden, J	1
Bevin, AG	1
Smith, HC	1
Grisk, A	1
Hegewald, G	1
Emmrich, R	1
Häntzschel, HJ	1
Häntzschel, H	1
Ronzoni, G	1
Alcini, E	1
Pirozzi, V	1
Zucchetti, E	1
Wiel Marin, A	1
Takeuchi, T	1
Prockop, DJ	1
Varga, F	1
Méhes, G	1
Molnár, Z	1
Bengmark, S	1
Ekdahl, PH	1
Gottfries, A	1
Mobacken, H	1
Rehnström, B	1
Scherstén, T	1
Pine, EK	1
Holland, JF	1